Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Other Non-Current Liabilities (2017 - 2025)

Regen BioPharma (RGBPP) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 35.18% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 35.18% increase, with the full-year FY2025 number at $2.1 million, up 48.11% from a year prior.
  • Other Non-Current Liabilities was $2.5 million for Q4 2025 at Regen BioPharma, up from $2.1 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $70.6 million in Q1 2022 to a low of $302391.0 in Q1 2021.
  • A 5-year average of $5.9 million and a median of $1.7 million in 2025 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 23234.63% in 2022, then tumbled 98.02% in 2023.
  • Regen BioPharma's Other Non-Current Liabilities stood at $3.9 million in 2021, then plummeted by 63.44% to $1.4 million in 2022, then decreased by 2.5% to $1.4 million in 2023, then soared by 30.01% to $1.8 million in 2024, then soared by 35.18% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Other Non-Current Liabilities are $2.5 million (Q4 2025), $2.1 million (Q3 2025), and $1.8 million (Q2 2025).